Nothing Special   »   [go: up one dir, main page]

HUP0001930A3 - Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna - Google Patents

Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna

Info

Publication number
HUP0001930A3
HUP0001930A3 HU0001930A HUP0001930A HUP0001930A3 HU P0001930 A3 HUP0001930 A3 HU P0001930A3 HU 0001930 A HU0001930 A HU 0001930A HU P0001930 A HUP0001930 A HU P0001930A HU P0001930 A3 HUP0001930 A3 HU P0001930A3
Authority
HU
Hungary
Prior art keywords
tnfalpha
molecules
modified
dna
vaccines
Prior art date
Application number
HU0001930A
Other languages
English (en)
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of HUP0001930A2 publication Critical patent/HUP0001930A2/hu
Publication of HUP0001930A3 publication Critical patent/HUP0001930A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0001930A 1997-04-15 1998-04-15 Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna HUP0001930A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
PCT/DK1998/000157 WO1998046642A1 (en) 1997-04-15 1998-04-15 MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA

Publications (2)

Publication Number Publication Date
HUP0001930A2 HUP0001930A2 (hu) 2000-09-28
HUP0001930A3 true HUP0001930A3 (en) 2001-10-29

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001930A HUP0001930A3 (en) 1997-04-15 1998-04-15 Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna

Country Status (30)

Country Link
US (1) US7118750B1 (hu)
EP (1) EP0975668B1 (hu)
JP (1) JP2001521386A (hu)
KR (1) KR100522289B1 (hu)
CN (1) CN1178955C (hu)
AR (1) AR012427A1 (hu)
AT (1) ATE326481T1 (hu)
AU (1) AU743400B2 (hu)
BR (1) BR9811462A (hu)
CA (1) CA2289476A1 (hu)
CZ (1) CZ9903657A3 (hu)
DE (1) DE69834556T2 (hu)
DK (1) DK0975668T3 (hu)
EE (1) EE9900461A (hu)
ES (1) ES2264569T3 (hu)
HK (1) HK1022918A1 (hu)
HR (1) HRP980203B1 (hu)
HU (1) HUP0001930A3 (hu)
IL (1) IL132281A0 (hu)
NO (1) NO995002L (hu)
NZ (1) NZ337955A (hu)
PL (1) PL194221B1 (hu)
RU (1) RU2241715C2 (hu)
SI (1) SI0975668T1 (hu)
SK (1) SK285639B6 (hu)
TR (1) TR199902562T2 (hu)
TW (1) TW510921B (hu)
UA (1) UA72440C2 (hu)
WO (1) WO1998046642A1 (hu)
ZA (1) ZA983148B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
DK1159003T3 (da) * 1999-03-02 2011-02-07 Centocor Inc Anti-tnfalfa-antistoffer til terapi af steroid-resistent astma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
CN1384757A (zh) 1999-07-20 2002-12-11 法麦克萨有限公司 下调gdf－8活性的方法
WO2001097837A1 (en) * 2000-06-21 2001-12-27 Ferring Bv Solubilised protein vaccines
WO2003075951A2 (en) * 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
AU2004209981B2 (en) * 2003-02-01 2009-02-26 Janssen Sciences Ireland Uc Active immunization to generate antibodies to soluble A-beta
WO2005084198A2 (en) * 2004-02-27 2005-09-15 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
TWI399383B (zh) 2005-05-16 2013-06-21 Abbott Biotech Ltd ＴＮＦα抑制劑於治療侵蝕型多發性關節炎之用途
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
BR112012010698A2 (pt) 2009-11-05 2016-11-29 Uab Research Foundation método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
RU2013125147A (ru) 2010-12-08 2015-01-20 Неовакс Сильно инактивированная иммуногенная вакцина, сохраняющая высокую иммуногенность, и способ ее изготовления
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
CA2985108A1 (en) 2015-05-05 2016-11-10 Rubicon Biotechnology Llc Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0251037B1 (en) 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
AU743400B2 (en) 2002-01-24
AR012427A1 (es) 2000-10-18
CZ9903657A3 (cs) 2001-09-12
TR199902562T2 (xx) 2000-02-21
CN1178955C (zh) 2004-12-08
DE69834556D1 (de) 2006-06-22
BR9811462A (pt) 2000-09-12
EP0975668A1 (en) 2000-02-02
PL336295A1 (en) 2000-06-19
CN1252809A (zh) 2000-05-10
EP0975668B1 (en) 2006-05-17
SI0975668T1 (sl) 2007-02-28
KR20010006416A (ko) 2001-01-26
NZ337955A (en) 2000-09-29
KR100522289B1 (ko) 2005-10-19
PL194221B1 (pl) 2007-05-31
US7118750B1 (en) 2006-10-10
DE69834556T2 (de) 2007-05-10
HRP980203B1 (en) 2003-04-30
SK140999A3 (en) 2000-06-12
ATE326481T1 (de) 2006-06-15
SK285639B6 (sk) 2007-05-03
ZA983148B (en) 1999-10-15
EE9900461A (et) 2000-06-15
JP2001521386A (ja) 2001-11-06
IL132281A0 (en) 2001-03-19
DK0975668T3 (da) 2006-09-25
HK1022918A1 (en) 2000-08-25
TW510921B (en) 2002-11-21
WO1998046642A1 (en) 1998-10-22
UA72440C2 (en) 2005-03-15
NO995002L (no) 1999-12-15
CA2289476A1 (en) 1998-10-22
RU2241715C2 (ru) 2004-12-10
HUP0001930A2 (hu) 2000-09-28
AU7030398A (en) 1998-11-11
ES2264569T3 (es) 2007-01-01
HRP980203A2 (en) 1998-12-31
NO995002D0 (no) 1999-10-14

Similar Documents

Publication Publication Date Title
HUP0001930A3 (en) Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna
EP1490386A4 (en) NEW POLYPEPTIDES AND THESE ENCODING NUCLEIC ACIDS
HUP0104296A3 (en) Cross-linked hyaluronic acids, uses thereof and biological substances containing them
IL178210A0 (en) Polypeptides and nucleic acids encoding the same
AU3274995A (en) Fibrin-binding peptides, dna coding therefor and uses thereof
HUP0201783A3 (en) Anti-alfavbetha3 recombinant human antibodies, nucleic acids encoding same and methods
IL112453A0 (en) Human repair proteins, dna(rna) encoding them and their preparation
IL136696A0 (en) Sigirr dna and polypeptides
EP1001964A4 (en) TANGO-78, TANGO-79 AND TANGO-81 NUCLEIC ACID MOLECULES
EP1117436A4 (en) NEISSERIA SPP. POLYPEPTIDES, NUCLEIC ACID SEQUENCE AND THEIR USE
EP1047773A4 (en) CUBILIN PROTEIN, DNA SEQUENCES ENCODING CUBILIN AND THEIR USE
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
EP1117761A4 (en) MNR2 coding gene and method
GB9421093D0 (en) Hippocampus-associated proteins, DNA sequences coding therefore and uses thereof
EP1109824A4 (en) BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM
EP1044216A4 (en) DNA MOLECULES ENCODING HUMAN NUCLEAR RECEPTOR PROTEINS, nNR7 AND nNR7-1
IL137493A0 (en) Svph3-13 and spvh3-17 dna and polypeptides
GB9824357D0 (en) Protein and DNA coding therefor
EP1142999A4 (en) PROTEIN AND ITS DNA
EP1012160A4 (en) TANGO-72 AND TANGO-77 NUCLEIC ACID AND POLYPEPTID MOLECULES
EP1141025A4 (en) NEW HYALURONAN-BINDING PROTEINS AND CODING GENES
EP1063290A4 (en) NEW DICARBOYL REDUCTASE AND GENERAL CODING FOR IT
EP1007540A4 (en) DNA MOLECULES ENCODE PROTEINS OF THE HUMAN CORE RECEPTOR
IL140030A0 (en) Polypeptides dna molecules encoding them
IL124567A0 (en) Hemorrhagic enteritis virus dna sequences proteins encoded thereby and various uses thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees